Cargando…
Reducing mortality from 2019-nCoV: host-directed therapies should be an option
Autores principales: | Zumla, Alimuddin, Hui, David S, Azhar, Esam I, Memish, Ziad A, Maeurer, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133595/ https://www.ncbi.nlm.nih.gov/pubmed/32035018 http://dx.doi.org/10.1016/S0140-6736(20)30305-6 |
Ejemplares similares
-
Toning down the 2019-nCoV media hype—and restoring hope
por: Ippolito, Giuseppe, et al.
Publicado: (2020) -
The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China
por: Hui, David S., et al.
Publicado: (2020) -
Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections
por: Zumla, Alimuddin, et al.
Publicado: (2015) -
Human Coronavirus Infections—Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and SARS-CoV-2
por: Hui, David S., et al.
Publicado: (2022) -
Immunometabolism and Pulmonary Infections: Implications for Protective Immune Responses and Host-Directed Therapies
por: Rao, Martin, et al.
Publicado: (2019)